Cancer Therapy Pathways reward incentive ending

Beginning Jan. 1, 2026, the reward incentive for our Cancer Therapy Preferred Pathways program will be discontinued. However, Cancer Therapy Preferred Pathways will continue to be included in the Cancer Guidance Program and shown as a cancer therapy preferred pathway in the Prior Authorization Tool, also known as MBMNow.

We’ll also pay Cancer Therapy Preferred Pathways reward incentives earned through the end of 2025. If you qualify for a reward and timely attest, you will receive your reward check by April 30, 2026.

We’ll also continue to use Cancer Therapy Preferred Pathways selection (when available), as one of the quality metrics measured in our Oncology Pay for Performance program.